Rasagiline 1mg tablets
Requires a prescription from a doctor or prescriber
Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Rasagiline
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Rasagiline
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
33 branded products available
MHRA licensed products
View all licensed products for Rasagiline on the MHRA register
Azilect 1mg tablets
Azilect 1mg tablets
Rasagiline 1mg tablets
Rasagiline 1mg tablets
Rasagiline 1mg tablets
Rasagiline 1mg tablets
Rasagiline 1mg tablets
Rasagiline 1mg tablets
Rasagiline 1mg tablets
Rasagiline 1mg tablets
Rasagiline 1mg tablets
Rasagiline 1mg tablets
This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.
View full Drug TariffSource: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.
WHO defined daily dose (DDD)
1 mg
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary BNF/ATC mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(1)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 17 · Randomised trials: 8 · 2002–2025
Showing the 50 most relevant studies, sorted by most relevant.
O Rascol, DJ Brooks, E Melamed, et al.
The Lancet, 2005
Seppänen P, Forsberg MM, Tiihonen M, et al.
2024
Antonio J Garcia Ruiz, Ester Morales Garcia, Maria Jose Gomez Heredia, et al.
Journal of Comparative Effectiveness Research, 2025
- Parkinson Disease
- Benzylamines
- Indans
Aim: This systematic review aimed to evaluate the comparative efficacy, safety and cost-effectiveness of safinamide (50/100 mg) versus rasagiline (1 mg) in managing Parkinson’s disease (PD). Materials & methods: Randomized clinical trials were identified through systematic searches of PubMed, Embase and Cochrane databases (last searched September 2023). Eligibility criteria included studies assessing Unified Parkinson’s Disease Rating Scale (UPDRS) scores, On/Off time and adverse events. Risk of bias was evaluated using funnel plots, and data synthesis employed odds ratios, number needed to treat (NNT) and incremental cost-effectiveness ratios, calculated using the current costs of safinamide and rasagiline in Spain. Results: Thirteen trials (n = 4157 participants) were included. Safinamide demonstrated greater efficacy (NNT-UPDRS: 6 vs 8) and safety (number needed to harm-serious adverse events: 135 vs 83) compared with rasagiline. The benefit-risk balance of safinamide was superior, as evidenced by higher likelihood of being helped over harmed ratios. Cost-effectiveness analysis revealed lower costs per NNT for On/Off time with safinamide. While rasagiline treated more patients within a fixed budget, safinamide achieved better responder-to-nonresponder ratios. Conclusion: Safinamide showed superior efficacy, safety and cost-efficiency compared with rasagiline, supporting its use as a preferred adjunct therapy for PD. Limitations include reliance on clinical trial data and Spanish cost models. Future research incorporating real-world evidence is warranted.
Abstract licence: CC BY-NC-ND
Deqi Jiang, Hua-Kun Wang, Y. Wang, et al.
Neurological Sciences, 2019
Ying Chang, Li-Bo Wang, Dan Li, et al.
Annals of Medicine, 2017
Hao Chang, Ying-Yu Li, C. Hong, et al.
Journal of Psychopharmacology, 2022
R. Hauser, V. Abler, E. Eyal, et al.
International Journal of Neuroscience, 2016
O. Kano, H. Tsuda, A. Hayashi, et al.
Parkinson's Disease, 2022
A. Ludolph, Joachim Schuster, J. Dorst, et al.
The Lancet. Neurology, 2018
P. Barone, G. Santangelo, L. Morgante, et al.
European Journal of Neurology, 2015
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
150 found
Half-life
3 hours
Mechanism
The precise mechanisms of action of rasagiline is unknown.
Food interactions
3 warnings
Human targets
2 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
36%
Half-life
3 hours
Protein binding
88-94%
Volume of distribution
87 L
Metabolism
Elimination
62%
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 1910 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
Less than 1% of rasagiline was excreted as unchanged drug in urine.
Proteins and enzymes this drug interacts with in the body
PMID:11049757 PMID:11134050 PMID:20493079 PMID:8316221 PMID:8665924
Preferentially degrades benzylamine and phenylethylamine PMID:11049757 PMID:11134050 PMID:20493079 PMID:8316221 PMID:8665924
PMID:1508712 PMID:8183370
Regulates cell death by controlling the mitochondrial membrane permeability .
PMID:11368354
Appears to function in a feedback loop system with caspases .
PMID:11368354
Inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating factor (APAF-1) .
PMID:11368354
Also acts as an inhibitor of autophagy: interacts with BECN1 and AMBRA1 during non-starvation conditions and inhibits their autophagy function .
PMID:18570871 PMID:20889974 PMID:21358617
May attenuate inflammation by impairing NLRP1-inflammasome activation, hence CASP1 activation and IL1B release PMID:17418785
Enzymes involved in drug metabolism — important for understanding drug interactions
ATC N04BD02
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Rasagiline
Additional database identifiers
Drugs Product Database (DPD)
19840
ChemSpider
2314553
BindingDB
10989
PDB
RAU
ZINC
ZINC000019875504
HUGO Gene Nomenclature Committee (HGNC)
HGNC:6834
GenAtlas
MAOB
GeneCards
MAOB
GenBank Gene Database
S62734
GenBank Protein Database
398415
Guide to Pharmacology
2490
UniProt Accession
AOFB_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:990
GenAtlas
BCL2
GeneCards
BCL2
GenBank Gene Database
M13994
GenBank Protein Database
179367
Guide to Pharmacology
2844
UniProt Accession
BCL2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2596
GenAtlas
CYP1A2
GeneCards
CYP1A2
GenBank Gene Database
Z00036
Guide to Pharmacology
1319
UniProt Accession
CP1A2_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
ATC classifications (Wikidata)
Linked open data from Wikidata (Q420685), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication. WHO INN from the World Health Organization.